Interestingly, combination of M3, Methylation-burden and KRAS-mutation reached the best performance for all patients (AUC: 0.920), especially for early CRC patients (AUC: 0.931), which possessed the same predictive efficiency with the combination of four factors. This evidence concerns the gene KRAS and colorectal carcinoma.